In Corporate Livewire‘s June 2013 Round Table “Biotech & Pharmaceutical,” Dr. Gregory Bell and other leading experts discuss changes and analyze the effects they will have in the industry.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.